These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8877849)

  • 1. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma.
    Murayama N; Tanaka S; Kikuchi T; Nakaoka M; Sudo K
    J Pharm Biomed Anal; 1996 Aug; 14(11):1435-45. PubMed ID: 8877849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction.
    Murayama N; Sudo K
    J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):389-96. PubMed ID: 9188828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodecarboxylation of DX-9065a, a new factor Xa inhibitor, in aqueous solution.
    Kawai Y; Matsubayashi K
    Chem Pharm Bull (Tokyo); 1998 Jan; 46(1):131-5. PubMed ID: 9468645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
    Chino D; Fujita Y; Ishii K; Nakayama K
    J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose.
    Murayama N; McMahon H; Young CG; McCracken NW; Okamura Y; Hakusui H; Tanaka M
    Xenobiotica; 2000 May; 30(5):515-21. PubMed ID: 10875684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
    Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
    Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunoassay for DS-4574, an antiallergic agent: development, evaluation, and application to human plasma samples.
    Murayama N; Nakaoka M; Nomura H; Hakusui H
    J Pharm Sci; 1994 Nov; 83(11):1574-7. PubMed ID: 7891277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans.
    He H; McKay G; Wirshing B; Midha KK
    J Pharm Sci; 1995 May; 84(5):561-7. PubMed ID: 7658345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
    Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
    Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-am idino- 2- naphthyl)propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis.
    Vaz RJ; McLean LR; Pelton JT
    J Comput Aided Mol Des; 1998 Mar; 12(2):99-110. PubMed ID: 9690170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
    Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.